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evier B.VAbstract Aim of the work: This randomized controlled study was designed to compare the effec-
tiveness of local injection of autologous platelet rich plasma (PRP) and local steroid in reducing
pain and improving function in a cohort of patients with tennis elbow (TE) and plantar fasciitis
(PF).
Patients and methods: The study population comprised two groups; Group 1 patients with TE
(n= 30) and Group 2 patients with PF (n= 30). In each group patients were allocated randomly
to receive either a steroid or PRP injections. All patients ﬁlled in visual analog scale (VAS),
disability of arm, shoulder and hand (DASH) score for TE and foot health status questionnaire
(FHSQ) for PF at base line and after 6 weeks.
Results: Relative to TE group of patients signiﬁcant differences were observed between VAS and
DASH scores at base line and 6 weeks after treatment in both groups (p< 0.001). While no signif-
icant differences were observed relative to VAS and DASH score changes between both groups
(p> 0.05). In PF patients comparison of VAS and FHSQ at base line and 6 weeks after treatment
between control group and PRP group showed signiﬁcant differences for VAS (p= 0.005 andom (A.S. Omar).
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44 A.S. Omar et al.p< 0.001, respectively), and for FHSQ (p= 0.03 and p< 0.001, respectively). While highly signif-
icant difference were observed between both groups regarding VAS and FHSQ changes
(p= 0.001).
Conclusion: Local injection of autologous PRP proved to be a promising form of therapy for TE
and PF. It is both safe and effective in relieving pain and improving function and superior to local
steroids in PF.
 2012 Egyptian Society for Joint Diseases and Arthritis. Production and hosting by Elsevier B.V.
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The most common overuse syndrome is related to excessive
wrist extension and commonly referred to as tennis elbow
(TE), although more common in non-tennis players. Typically,
TE affects individuals greater than age 40 years with a history
of repetitive activity aggravating the extensor tendons of the
forearm. It is also commonly referred to as ‘‘lateral epicondy-
litis’’, but this is usually a misnomer because, in general, micro-
scopic evaluation of the tendons does not show signs of
inﬂammation, but rather angioﬁbroblastic degeneration and
collagen disarray. On histological level light microscopy re-
veals both an excess of ﬁbroblasts and blood vessels that are
consistent with neovessels or angiogenesis [1]. The tendons
are relatively hypovascular proximal to the tendon insertion.
This hypovascularity may predispose the tendon to hypoxic
tendon degeneration and has been implicated in the etiology
of tendinopathies [2].
On the other hand, chronic plantar fasciitis (PF) is the most
common cause of foot complaints and, making up 11–15% of
the foot symptoms requiring professional care among adults
[3]. The incidence of PF peaks in people between the ages of
40–60 years with no bias towards either sex [4]. The underlying
condition that causes PF is a degenerative tissue condition that
occurs near the site of origin of the plantar fascia at the medial
tuberosity of the calcaneous [5]. Steroid injections are a popu-
lar method of treating the condition but only seem to be useful
in the short term and only to a small degree [6].
The introduction of platelet rich plasma (PRP) as a possible
adjunct to conservative and operative treatment has motivated
signiﬁcant research in the topic [7]. PRP is promoted as an
ideal autologous biological blood-derived product, which can
be exogenously applied to various tissues where it releases high
concentrations of platelet derived growth factors that enhance
wound, bone and also tendon healing [8].
In an animal model the addition of growth factors to the
ruptured tendon has been shown to increase tendon healing
[9,10]. In humans it offers encouraging results of an alternative
minimally invasive treatment that addresses the pathophysiol-
ogy of TE that has failed traditional nonsurgical modalities [8].
It was also demonstrated that a single injection of PRP im-
proves pain and function more than corticosteroid injection
and these improvements were sustained over time with no
reported complications [11].
Relative to PF the injection of PRP into the affected tissue
addresses the healing stages necessary to reverse the degenera-
tive process which are going on in the base of the plantar fas-
cia. Moreover the treatment of tendinosis with an injection of
PRP may be a nonoperative alternative. This treatment con-
cept directly addresses the existing condition and should proveto be a superior alternative to current conservative treatments
for chronic PF [12].
All theses new lines of evidences inspired us to evaluate the
effectiveness of local injection of autologous PRP in reducing
pain and improving function in patients with TE and PF com-
pared with local injection of corticosteroid.
2. Patients and methods
This randomized clinical study was carried out in the Rheuma-
tology and Rehabilitation outpatient clinic in Suez Canal Uni-
versity Hospital from October 2009–May 2010. A total of 60
patients were recruited for the study, with 30 cases had TE
(Group I) and another 30 cases had PF (Group II). In each
group, patients were allocated randomly to receive either a ste-
roid injection (n= 15) (control group) or PRP injection
(n= 15) (PRP group).
2.1. Clinical assessment
Thirty patients diagnosed as having TE and 30 with PF of both
genders, aged above 18 years (for TE: having pain and tender-
ness over the lateral aspect of the elbow, which is related to
activity level, with a positive wrist extension test, for PF: hav-
ing inferior heel pain that is usually worse with their ﬁrst steps
in the morning or after a period of inactivity, with maximal
tenderness over the anteromedial aspect of the inferior heel).
None of our patients received local steroid injections, non-
steroidal anti-inﬂammatory at least 4 weeks prior to the study.
Patients with history of anemia (hemoglobin <7.0 g/dl),
thrombocytopenia (platelets <150 · 103 lL) or bleeding dys-
crasias, signiﬁcant cardiovascular, renal or hepatic disease, (lo-
cal) malignancy were excluded. In PF group of patients further
exclusion criteria were; previous surgery for PF, vascular insuf-
ﬁciency or neuropathy related to heel pain, hypothyroidism
and diabetics.
All included patients on the 1st visit were evaluated by a full
medical history and physical examination then marked the le-
vel of pain on the visual analog scale (VAS) (0–10). The score
records the patient’s reported pain using a scale of 0–10, where
0 is pain-free and 10 is the worst pain imaginable. The score
will be marked at the point on the line that corresponds with
the patient’s response.
2.2. Radiographic assessment
All affected patients in both groups were screened with stan-
dard X-ray projections. The aim is to exclude calciﬁc tendinitis
or other pathology in case of TE and to exclude bony abnor-
malities of the calcaneus in case of PF.
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the disability of Arm, Shoulder and Hand (DASH) score
[13]. The DASH questionnaire is a standardized regional out-
come measure that captures upper extremity disability from
the perspective of the patient and is used to study clinical out-
come in musculoskeletal disorders. The DASH has been
shown to be a reliable, valid and responsive tool for evaluating
both proximal and distal disorders, conﬁrming its usefulness
across the whole extremity. While functional assessment for
PF patients was assessed by the foot health status question-
naire (FHSQ) [14].
After the procedure all patients were instructed to rest the
elbow and wrist (in cases of TE) and to avoid weight bearing
(in cases of PF) for 48 h with a subsequent increase in ambu-
lation over the next days. Patients instructed to receive
acetaminophen for pain while the use of any non-steroidal
anti-inﬂammatory medication is strictly prohibited. PF pa-
tients were allowed to return to a comfortable shoe after two
days. Six weeks later, all patients were re-evaluated and reﬁlled
VAS and DASH score for TE patients and FHSQ for PF
patients.
2.3. Preparation of PRP
A closed system was used throughout the process to avoid con-
tamination, at least 24 h before injection. Into quadruple pedi-
atric blood bag system containing 63 ml citrate phosphate
dextrose (CPD) as an anticoagulant [JMS Singapore Ltd.],
150 ml bloods withdrawn from TE and PF patients after
adjusting CPD volume in the original pack to 21 ml, passing
excess anticoagulant to the distal satellite pack (JMS hemo-
scale was used for shacking and adjusting the donated vol-
ume). From donated blood in one satellite pack, PRP
separated by two-step centrifugation at ambient temperature
[for 15 min at 320g (soft spin) then at 2000g for 15 min (hard
spine)] and kept at +200 C with continuous shaking on a hor-
izontal shaker (Forma Scientiﬁc, Marietta, oH). The platelet
count was done using Cell Dyne 1700 (ABBOT Diagnostics,
USA) before and after preparation. Accepted PRP contained
at least two times increase in platelet concentration [15].
All patients gave an informed written consent, which was
approved by local ethical committee in our university.
Statistical analysis: Quantitative variables were described
using mean ± standard deviation (SD) and categorical data
by frequency and percentage. Student’s t-test was used to com-
pare quantitative variables between groups of patients. Le-
vene’s test for equality of variances and t-test for equality of
means were used to examine the changes of VAS, DASH score
and FHSQ at base line and at follow-up after treatment. In all
tests, p value <0.05 was considered to be statistically
signiﬁcant.3. Results
The mean age of the control group in TE patients was
37.5 ± 17.5 years, and in PRP patients were 40.5 ± 15.5 years.
The control group includes 5 males and 10 females, while the
PRP group includes 6 males and 9 females. The mean age of
the control group in PF patients was 44.5 ± 15.5 years, and
among PRP group were 42.5 ± 17.5 years. All patients in withPF were females. In the control group, 7 patients had right heel
affection, and 8 had affection of the left heel. In the PRP group,
11 patients had right heel affection and 4 had affection of the
left heel.
Table 1 compares the mean VAS and DASH scales during
1st and 2nd visit among patients with TE. Highly signiﬁcant
differences were observed between both groups relative to
VAS and DASH scores before (1st visit) and 6 weeks after
treatment (2nd visit), (p< 0.001) (Fig. 1a–d). While compari-
sons of VAS and DASH scores changes among control and
PRP groups of patients showed insigniﬁcant differences rela-
tive to the outcome measures evaluated (p> 0.05).
Table 2 compares the mean VAS and FHSQ score scores
during 1st and 2nd visit in PF group of patients. Signiﬁcant
differences were observed between both groups relative to
VAS assessment (1st visit versus 2nd visit) in both control
group (p= 0.005) and PRP group of patients (p= 0.03). Rel-
ative to FHSQ score highly signiﬁcant differences were ob-
served between control group and PRP group of patients
(p< 0.001), (Fig. 2a–d).
While comparisons of VAS and FHSQ score changes
among control and PRP groups of patients with PF showed
no signiﬁcant difference between both groups regarding base
line VAS (p= 0.152) and baseline FHSQ (p= 0.761). While
highly signiﬁcant difference were observed between both
groups regarding VAS 2nd visit (p< 0.001) and FHSQ 2nd
visit (p= 0.001) and another highly signiﬁcant difference be-
tween both groups regarding VAS and FHSQ changes
(p= 0.001). However PRP treated group of patients showed
much signiﬁcant improvement compared to control group
reﬂecting better efﬁcacy.4. Discussion
The current study revealed that local injection of PRP, which is
a novel form of treatment, provides signiﬁcant relief of pain
and improvement in function that is comparable to the steroid
injection in treatment of TE and more superior in treatment of
PF compared to local steroid injection. Moreover, it provides a
safer option for patients who have contraindications to steroid
therapy (e.g. diabetics), and an option for patients who are
considered for surgical intervention.
Although refractory chronic tendinopathy may be respon-
sive to PRP injection, yet the data available to date are lim-
ited by quality and size of study, as well as length of follow-
up, and are currently insufﬁcient to recommend this modal-
ity for routine clinical use [16]. However autologous PRP
was proved to improve the early neotendon properties [17]
and improve tissue healing by enhancing cellular chemotaxis,
proliferation and differentiation, removal of tissue debris,
angiogenesis, and the laying down of extracellular matrix
[18].
Relative to TE our results conﬁrm the suggested positive ef-
fect in vivo as described by Mishra and Pavelko [19]. In their
report a signiﬁcant improvement of symptoms after 8 weeks
in 60% of the patients treated with PRP. At 6 months, PRP
treated patients, noted 81% improvement in their visual ana-
log pain scores (p= .0001). In another study Edwards and
Calandruccio [8] reported that 22 patients (79%) with TE in
whom nonsurgical modalities had failed were relieved
completely of pain even during strenuous activity. Their study
Table 1 Comparison of TE patients regarding VAS and DASH scores in both control and PRP treated groups.
Parameter TE (control group) mean ± SD p value TE (PRP group) mean ± SD p value
1st visit 2nd visit 1st visit 2nd visit
VAS (0–10) 8.6 ± 1.6 4.3 ± 2.1 <0.001** 8.0 ± 1.4 3.8 ± 1.9 <0.001**
DASH score 57.3 ± 10.3 20.2 ± 14.0 <0.001** 58.9 ± 10.5 19.9 ± 12.9 <0.001**
VAS, visual analog score; TE, tennis elbow; PRP, platelet rich plasma; DASH, disability of arm, shoulder and hand score.
** Highly signiﬁcant (p< 0.001).
Figure 1 Boxplots showing the signiﬁcant difference between visual analog scale (VAS) and disability of arm, shoulder and hand
(DASH) scores (1st visit) versus (2nd visit) in both control group and PRP group of patients with TE.
Table 2 Comparison of PF patients regarding visual analog score and foot health status questionnaire in control and PRP treated
groups.
Parameter PF (steroid treated group) mean ± SD p value PF (PRP treated group) mean ± SD p value
1st visit 2nd visit 1st visit 2nd visit
VAS (0–10) 8.8 ± 0.9 6.5 ± 2.6 0.005* 8.2 ± 1.3 2.6 ± 2.1 <0.000**
FHSQ score 57.5 ± 9.4 49.0 ± 19.1 0.030* 58.5 ± 9.6 25.1 ± 12.4 <0.000**
VAS, visual analog scale; PF, plantar fasciitis; PRP, platelet rich plasma; FHSQ, foot health status questionnaire.
* Signiﬁcant (p< 0.05).
** Highly signiﬁcant (p< 0.001).
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Figure 2 Boxplots showing the signiﬁcant difference between VAS and foot health status questionnaire (FHSQ) scores (1st visit) versus
(2nd visit) in both control group and PRP group of patients with PF.
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treatment that addresses the pathophysiology of TE that has
failed traditional nonsurgical modalities.
In our study we observed highly signiﬁcant differences be-
tween both groups relative to VAS and DASH scores before
and 6 weeks after treatment (p< 0.001) while comparisons
of VAS and DASH changes among control and PRP groups
of patients showed insigniﬁcant differences (p> 0.05). Our re-
sults are in agreement with that observed by Peerbooms et al.
[11] who reported that, 24 of the 49 patients (49%) in the cor-
ticosteroid group and 37 of the 51 patients (73%) in the PRP
group were successful (p < 0.001). Furthermore, in their study
according to the DASH scores, 25 of the 49 patients (51%) in
the corticosteroid group and 37 of the 51 patients (73%) in the
PRP group were successful (p = 0.005). Important to note in
their study is that the corticosteroid group was better initially
and then declined, whereas the PRP group progressively im-
proved. In the most recent work treatment of patients with
chronic TE with PRP reduces pain and increases function sig-
niﬁcantly, exceeding the effect of corticosteroid injection even
after a follow-up of 2 years [20]. The later ﬁndings explain efﬁ-
cacy and longstanding improvement of this promising thera-
peutic option. Nevertheless Finnoff et al. [21] observed that
PRP injection following ultrasound guided percutaneous nee-dle tenotomy for TE was associated with sonographically
apparent improvements in tendon morphology.
In fact, histology of chronic cases with PF has shown no
signs of inﬂammatory cell invasion into the affected area.
The tissue instead is characterized histologically by inﬁltration
with macrophages, lymphocytes, and plasma cells; tissue
destruction; and repair involving immature vascularization
and ﬁbrosis .The normal fascia tissue is replaced by an angio-
ﬁbroblastic hyperplastic tissue which spreads itself throughout
the surrounding tissue creating a self-perpetuating cycle of
degeneration [22]. Steroid injections are a popular method of
treating the condition but only seem to be useful in the short
term and only to a small degree [6]. However treatment with
corticosteroids has a high frequency of relapse and recurrence,
probably because intra fascial injection may lead to permanent
adverse changes within the structure of the fascia and because
patients tend to overuse the foot after injection as a result of
direct pain relief [23]. Additionally and more seriously is that
repeated corticosteroids injections could predispose to rupture
of the plantar fascia and consequently surgical intervention.
The later complication was critically addressed in the study
by Acevedo and Beskin [24]. In their study a total of 765
patients with PF were evaluated. Fifty-one patients were
diagnosed with plantar fascia rupture, and 44 of these ruptures
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to conclude from their study is that thirty-nine of these pa-
tients were evaluated at an average 27-month follow-up. Thirty
patients (68%) reported a sudden onset of tearing at the heel,
and 14 (32%) had a gradual onset of symptoms. In most cases
the original heel pain was relieved by rupture. However, these
patients subsequently developed new problems including longi-
tudinal arch strain, lateral and dorsal midfoot strain, lateral
plantar nerve dysfunction, stress fracture, hammertoe defor-
mity, swelling, and/or antalgia.
In our study we observed signiﬁcant difference between
control and PRP group regarding VAS and FHSQ scores
(1st visit versus 2nd visit) and highly signiﬁcant difference
regarding VAS (p= 0.001) and FHSQ scores changes
(p< 0.001) between both groups. Importantly the PRP trea-
ted group showed much signiﬁcant improvement compared
to control group reﬂecting better efﬁcacy. However sustained
efﬁcacy should be further evaluated in longitudinal follow-up
studies.
In previous work Lee et al. [25] conducted prospective, ran-
domized, controlled, observer-blinded study over a period of
6 months. In their study Sixty-four patients were randomly
allocated to either the autologous blood or corticosteroid
treatment group. The authors reported that the reduction in
VAS for both groups was signiﬁcant over time (p< 0.0001).
At 6 weeks and 3 months, the corticosteroid group had signif-
icantly lower VAS than the PRP group (p< 0.011 and
p< 0.005, respectively), but the difference was not signiﬁcant
at 6 months. The authors concluded that intralesional autolo-
gous blood injection is efﬁcacious in lowering pain and tender-
ness in chronic PF, but corticosteroid is more superior in terms
of speed and probably extent of improvement. A forthcoming
randomized controlled multi center trial will be performed by
Peerbooms et al. [12]. The study population will consists of 120
patients of 18 years and older. Patients with chronic PF will be
allocated randomly to have a steroid injection or PRP injec-
tions. Data will be collected before the procedure, 4, 8, 12,
26 weeks and 1 year after the procedure. The authors postulate
that the concentrated growth factors work in a synergetic man-
ner to initiate a tendon healing response. Their authors sug-
gested that transforming growth factor b1 is shown to
signiﬁcantly increase type I collagen production by tendon
sheath ﬁbroblasts. This same mechanism is likely to be active
in chronic PF [26].
In conclusion, local injection of autologous PRP proved to
be a promising form of therapy for TE and PF. It is both safe
and effective in relieving pain and improving function. The
current available data support that repeated steroid injections
is deleterious and may lead to serious consequences .In our
study PRP treated group of patients with PF showed much sig-
niﬁcant improvement compared to steroid treated group
reﬂecting better efﬁcacy. However sustained efﬁcacy of this
promising and safer therapeutic option should be further eval-
uated in longitudinal follow-up studies that include larger
number of patients.5. Conﬂict of interest
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